Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 104

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 104
---
 functional/cross-functional teams. In addition to his role as a Director of
Radiopharm, Mr. Donnelly has been the Chief Financial Officer of PEPGEN Inc. since 2021. Prior to that, Mr. Donnelly was the Chief Financial
Officer of EIP Pharma, Inc. (currently CervoMed), from 2019 to 2021 and Vice President, R& D Business Operations at Takeda / Shire
PLC from 2004 to 2019. Mr. Donnelly received a B. A. in Science and Nuclear Engineering from the University of Massachusetts and a MBA
from the School of Business at Babson College.

Scientific Advisory Board

We have a scientific advisory
board that we consult periodically on the development of our product candidates and clinical trials.

Our
scientific advisory board is comprised of industry and academic experts familiar with our business and radiopharmaceuticals specifically,
and some are the technology founders of the underlying assets in the company’s portfolio. The current members of our advisory board
are:

  Dr. Sara Hurvitz (Professor of Medicine at UCLA and co-director of the                                                                                                          
  Dr. Ken Herrmann (certified Nuclear Medicine physician who also holds an executive MBA from the University of                                                                   
  Dr. Oliver Sartor (Director of Radiopharmaceutical Clinical Trials and Chair of Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic in Rochester, Minnesota).  

B. Compensation

Remuneration Principles

Remuneration of all executive
and non-executive directors and officers is determined by a committee of non-executive directors. The committee reviews and determines
our remuneration policy and structure annually to ensure it remains aligned to business needs and meets our remuneration principles. In
particular, the Board aims to ensure that remuneration practices are competitive and reasonable, enabling Radiopharm to attract and retain
key talent.

Key management personnel
may receive their fixed remuneration as cash, or cash with non-monetary benefits such as health insurance and car allowances. Fixed
annual renumeration is reviewed annually, or on promotion. It is benchmarked against market data for comparable roles in companies
in a similar industry and with similar market capitalization. The committee aims to position executives at or near the median, with
flexibility to take into account capability, experience, value to the organization and performance of the individual.

All executives are entitled
to participate in a short-term incentive plan that